Strengthening rare-disease pharmacovigilance with curated real-world data
By Lucy Fulford-Smith, Head of Pharmacovigilance & Medical Services [...]
Employing advanced analytics and artificial intelligence in rare-disease pharmacovigilance
By Lucy Fulford-Smith, Head of Pharmacovigilance & Medical Services [...]
The limits of traditional pharmacovigilance in rare diseases
By Lucy Fulford-Smith, Head of Pharmacovigilance & Medical Services [...]
The future of the rare disease landscape and the value of CRO support in this specialist area
The World Health Organization (WHO) defines a rare disease [...]
The role of pharmacovigilance in oncology drug trials
Some of our experts recently penned a thought-provoking article [...]